Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis [1]

New England Journal of Medicine

Volumn 363, Issue 12, 2010, Pages 1185-1186

  Armstrong, Matthew J ^a   Houlihan, Diarmaid D ^a   Rowe, Ian A ^a  

^a Centre for Liver Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PIOGLITAZONE; PLACEBO; ANTIOXIDANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; DOSE RESPONSE; HUMAN; LETTER; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; CARDIOVASCULAR DISEASE; FATTY LIVER; META ANALYSIS; NOTE; ANTIOXIDANT ACTIVITY; FOLLOW UP; LIVER INJURY; OXIDATIVE STRESS; VITAMIN SUPPLEMENTATION; BLOOD; METABOLISM;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HUMANS; META-ANALYSIS AS TOPIC; VITAMIN E; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS;

EID: 77956683216     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1006581     Document Type: Letter

References (5)

1. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:167585.
2. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:86573. (Pubitemid 46489550)
3. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010;51:3735. [Erratum, Hepatology 2010;51:1868.]
4. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:84257. [Erratum, JAMA 2008;299:7656.]
5. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:3746.